Frequently asked questions

CDC guidance citing USP General Chapter 797 states that an opened (needle-punctured) multi-dose vial should be dated and discarded within 28 days unless the manufacturer specifies another date, and that the date should never exceed the manufacturer's expiration date [1]. The Hospira bacteriostatic water label reviewed for this answer does not state its own in-use period, and it directs the use of aseptic technique for every entry [2]. Read more.

Tirzepatide is an agonist of both the GIP receptor and the GLP-1 receptor, whereas semaglutide acts on the GLP-1 receptor alone, and the labelled half-lives are approximately 5 days for tirzepatide and 1 week for semaglutide [1, 2]. In SURMOUNT-5, a phase 3b open-label trial of 751 adults with obesity but without type 2 diabetes, the mean weight change at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide [3]. The most common adverse events in both groups were gastrointestinal, mostly mild to moderate, and occurred primarily during dose escalation [3]. Read more.

Retatrutide is an investigational agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors [1, 2]. It has no FDA approval; phase 3 trial reports in obesity and in obesity with type 2 diabetes were published in 2026 [2, 3]. In a March 2026 warning letter, FDA treated retatrutide offered for sale on a website as an unapproved new drug [4]. Read more.

For both semaglutide and tirzepatide, the boxed warnings state that thyroid C-cell tumors occurred in rodents and that it is unknown whether the drugs cause such tumors, including medullary thyroid carcinoma, in humans [1, 2]. A 2026 review reported that emerging signals such as early worsening of diabetic retinopathy, muscle mass reduction, psychiatric symptoms and alopecia were identified mainly through observational and pharmacovigilance evidence [3]. For investigational agents such as retatrutide, the published phase 3 trials ran for 80 weeks, and longer-term safety data have not been published [4, 5]. Read more.

Gastrointestinal events are the most consistently reported: in the Wegovy label's pooled adult obesity trials, nausea occurred in 44% of treated participants versus 16% with placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11% [1]. The Zepbound label reports nausea in 25% to 29% across its three maintenance groups versus 8% with placebo [2]. Severe gastrointestinal adverse reactions were reported in 4.1% versus 0.9% (Wegovy) and in 1.7% to 3.1% versus 1% (Zepbound) [1, 2]. A 2026 narrative review identified gastrointestinal events as the principal cause of treatment discontinuation, and described gallbladder events and acute pancreatitis as infrequent [3]. Read more.

In the one head-to-head randomized trial identified (SURMOUNT-5), gastrointestinal events were the most common adverse events in both groups, mostly mild to moderate and concentrated in dose escalation [1]. The two labels report rates from separate trials with different designs, so their percentages (for example nausea 44% with Wegovy and 25% to 29% with Zepbound, versus 16% and 8% with placebo) are not a direct comparison [2, 3]. Both labels carry a boxed warning for thyroid C-cell tumors observed in rodents, with human relevance not determined [2, 3]. Read more.

These drugs delay gastric emptying, an effect that the tirzepatide label describes as largest after the first dose and diminishing over time [1]. Both labels instruct that a stepwise dose escalation be followed to reduce the risk of gastrointestinal adverse reactions [1, 2]. In SURMOUNT-5 the gastrointestinal events occurred primarily during dose escalation, and in the retatrutide phase 2 trial they were partially mitigated in groups with a lower starting dose [3, 4]. A 2026 review concluded that adverse events of this class mainly reflect predictable pharmacological effects rather than off-target toxicity [5]. Read more.

Reconstitution is the return of a freeze-dried product to solution by adding a diluent, which FDA's lyophilization guide notes requires a sterile diluent [1]. For an approved lyophilized peptide, the Egrifta SV label specifies using only the diluent supplied, inspecting the solution for particulate matter and discoloration, and administering immediately after reconstitution [2]. Diluent labels state that the volume to use depends on the specific drug and must follow the drug manufacturer's instructions [3]. Amiravo does not publish reconstitution volumes or procedures for unapproved compounds; supplier documentation is the relevant reference. Read more.

Bacteriostatic Water for Injection, USP is sterile, nonpyrogenic water for injection containing 0.9% or 1.1% benzyl alcohol added as a bacteriostatic preservative, supplied in multiple-dose containers from which repeated withdrawals may be made [1]. The label states it is indicated only for diluting or dissolving drugs for injection according to the drug manufacturer's instructions [1]. It also warns that benzyl alcohol has been associated with toxicity in neonates and that the product is not for use in neonates [1]. Read more.

Lyophilization, or freeze drying, is a process in which water is removed from a product after it is frozen and placed under vacuum, allowing ice to change directly to vapor [1]. FDA's inspection guide lists enhanced stability of a dry powder among its advantages and the need for sterile diluent on reconstitution among its disadvantages [1]. Read more.

Semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor [1]. GLP-1 receptors are present in brain areas involved in appetite regulation, and animal studies showed that semaglutide distributed to and activated neurons in regions regulating food intake [1]. Its elimination half-life is approximately one week, and the Wegovy label lists indications for reducing cardiovascular risk, reducing excess body weight and treating noncirrhotic MASH with moderate to advanced fibrosis in adults, the last under accelerated approval [1]. Read more.

No general period applies; it depends on the specific product. The Egrifta SV label directs that the solution be administered immediately after reconstitution, that unused solution be discarded, and that it not be frozen or refrigerated [1]. Diluent labels state that reconstituted solutions should not be stored unless the manufacturer of the dissolved drug directs otherwise [2, 3]. The 28-day limit in CDC guidance applies to an opened multi-dose diluent vial, not to a peptide solution made with it [4].

For one approved lyophilized peptide, the Egrifta SV label specifies room-temperature storage with excursions permitted between 15 and 30 degrees C [1]. FDA's inspection guide describes the dry state of a lyophilized powder as offering enhanced stability [2]. Liquid approved peptides tolerate limited unrefrigerated time per their labels, such as up to 28 days between 8 and 30 degrees C for Wegovy single-dose pens and up to 21 days at or below 30 degrees C for Zepbound single-dose pens [3, 4]. No published transit-stability study of research-grade lyophilized peptides was identified, so tolerance is product-specific and not established.

Bacteriostatic water contains benzyl alcohol (0.9% or 1.1%) as a preservative and is supplied in multiple-dose containers [1]. Sterile Water for Injection contains no bacteriostat, antimicrobial agent or added buffer, is supplied in single-dose containers, and the label warns that intravenous administration without added solute may cause hemolysis [2]. A 0.9% sodium chloride injection label describes a solution of 154 mEq/L sodium and 154 mEq/L chloride, with no antimicrobial agents, in single-dose containers for fluid and electrolyte replenishment [3]. Which diluent suits a given drug is specified by that drug's manufacturer [1, 2]. Read more.

Storage conditions are product-specific on FDA labels: the lyophilized product Egrifta SV is stored at 20 to 25 degrees C, with excursions to 15 to 30 degrees C permitted, in the original box to protect it from light [1]. Liquid approved peptides differ, with Wegovy kept refrigerated at 2 to 8 degrees C and Zepbound also refrigerated, both with limited permitted time at higher temperatures and no freezing [2, 3]. FDA's inspection guide lists enhanced stability of a dry powder as an advantage of lyophilization [4]. Unapproved research compounds have no FDA label, so supplier documentation is the available reference for their conditions.

A certificate of analysis is a supplier's report of the analytical tests performed on a specific lot; in FDA's current good manufacturing practice regulations, a manufacturer may accept a supplier's report of analysis in place of its own testing only if it conducts at least one specific identity test and validates the reliability of the supplier's analyses at appropriate intervals [1]. FDA also states that bulk drug substances used in 503A compounding must be accompanied by a valid certificate of analysis [2]. Read more.

It indicates that a laboratory ran a test aimed at fentanyl, usually at the seller's request; as of 22 October 2026 Amiravo has not found an FDA, DEA or USP requirement for such screening of peptide products. Its value depends on the method and its detection limit, which ICH Q2(R2) defines as the lowest amount that can be detected but not necessarily quantitated [1]. Read the guide.

A 2026 laboratory study of human growth hormone found that substantial aggregation occurred on freezing, with destabilization dominated by interfacial stresses during freezing [1]. The Wegovy and Zepbound labels both instruct not to freeze and not to use the product if it has been frozen [2, 3]. Aliquoting means dividing a stock solution into smaller portions so that each portion is thawed only once.

A COA is a supplier document, and under FDA's manufacturing regulations even a regulated manufacturer must validate a supplier's analyses at intervals rather than rely on the report alone [1]. Matching a batch number on a COA to a vial label shows that the documents correspond, which does not by itself establish that the analysis was accurate [1]. Studies of products bought online verified content and purity by independent laboratory methods, such as liquid chromatography-mass spectrometry, and found values that departed from labels [2, 3]. Read more.

Purity (the share of detected signal that is the target peptide) and content (the amount of peptide present) are different measurements, and because peptides commonly occur as salts with counter-ions, the weight of powder in a vial is not necessarily the weight of peptide [1]. In an analysis of melanotan II vials sold online, vials labeled as containing 10 mg held between 4.32 and 8.84 mg, with impurities of 4.1% to 5.9% in two of three shops [2]. In a semaglutide study, measured content exceeded labeled amounts by 28.56% to 38.69% while measured purity was 7.7% to 14.37% against a claimed 99% [3]. Read more.

The evidence base for both compounds is mainly preclinical: for BPC-157, a systematic review found 35 preclinical studies and one clinical study [1], and for the TB-500 fragment FDA reports no identified human exposure data [2]. Full-length thymosin beta-4 has been tested in humans in other formulations, including an eye-drop phase 2 trial and an intravenous phase 1 study in healthy volunteers, but those trials did not test the TB-500 fragment [3, 4]. Both compounds are named in the WADA Prohibited List [5]. No head-to-head comparison of the two compounds was identified. Read more.

Not at this time. Amiravo is an information library. Product pages describe compounds for research and educational purposes only and show “Information only” where a price would normally appear.

Cosmetic peptides are short synthetic sequences applied to skin and are grouped by function, for example as signal, carrier, neurotransmitter-modulating or enzyme-inhibiting peptides, and a review noted that their absorption may be poor and that clinical evidence for efficacy is often weak, so they are not interchangeable with injectable compounds [1]. Penetration of a cosmetic peptide into deeper skin layers has itself been a research question, which an FDA laboratory addressed in a skin-penetration study of one cosmetic peptide [2]. Injectable compounds are studied under different exposure conditions, such as BPC-157, whose pharmacokinetics were characterized after intravenous and intramuscular administration in rats and dogs [3]. Read more.

Several peptide drugs carry FDA-approved labels, including semaglutide (Wegovy), tirzepatide (Zepbound), tesamorelin (Egrifta SV) and bremelanotide (Vyleesi) [1, 2, 3, 4]. Compounds such as BPC-157, the thymosin beta-4 fragment sold as TB-500, CJC-1295 and epitalon appear in FDA compounding documents as bulk substances with limited or no identified human safety data, not as approved drugs [5]. WADA's 2026 list names BPC-157 as an example of a non-approved substance [6]. Read more.

A 2025 systematic review identified 36 studies, of which 35 were preclinical and 1 was clinical; in animal models the reviewed studies reported improved functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injury [1]. The one clinical study was a retrospective report of intra-articular use for chronic knee pain in which 7 of 12 patients reported relief for more than 6 months [1]. A 2026 systematic review found three human studies (30 participants in total), judged them to be of poor methodological quality and rated the certainty of evidence as very low [2]. No controlled efficacy trial with published results was identified in these reviews [1, 2]. Read more.

Thymosin beta-4 is a small protein of 43 amino acids described as the major actin-sequestering molecule in eukaryotic cells [1]. A doping-control laboratory identified the N-terminal acetylated 17-23 fragment of human thymosin beta-4 (Ac-LKKTETQ) in a product sold as TB-500 [2]. The LKKTETQ region contains the central actin-binding domain and has been associated in cell and animal work with angiogenesis, wound healing and cell migration [1]. FDA states it has not identified any human exposure data for drug products containing this fragment [3]. Read more.

Preclinical work has proposed that BPC-157 activates VEGFR2 and nitric oxide synthesis through an Akt-eNOS pathway, engages ERK1/2 signaling, and has anti-inflammatory effects [1]. These proposals come from animal and cell studies, and a systematic review described the mechanistic data as preclinical [2]. Human mechanistic data are extremely limited, and the review authors stated that rigorous large-scale trials are lacking [1]. Read more.

In rats and beagle dogs, the absolute bioavailability of BPC-157 after intramuscular injection was reported as approximately 14 to 19 percent in rats and 45 to 51 percent in dogs, with an elimination half-life under 30 minutes [1]. The three human reports identified in a 2026 systematic review each used a different route (intra-articular, intravesical and intravenous), so they do not permit a comparison of routes [2]. No controlled human study comparing administration sites for BPC-157 was identified [2]. Read more.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) described in the literature as originally isolated from gastric juice [1]. It has been studied mainly in animal models of musculoskeletal and gastrointestinal injury [1, 2]. It lacks FDA approval, and published human data consist of a small number of pilot or retrospective reports [2, 3]. Read more.

Peptides and proteins are both amino acid chains, and the practical difference is length: FDA's regulations define a protein as an alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size, so shorter chains fall on the peptide side of that line for US regulatory purposes [1]. The 40-residue cutoff is a regulatory definition rather than a sharp chemical boundary [1]. Read more.

In a published analysis of a melanotan II product, liquid chromatography with UV detection was used to quantify the peptide and its impurities, while tandem mass spectrometry confirmed identity from the retention time and the relative abundance of fragment ions [1]. Net peptide content refers to the amount of peptide itself, which can be quantified by methods such as amino acid analysis, a pharmacopeial technique used to quantify peptides and to determine identity from amino acid composition [2]. Endotoxin testing measures bacterial endotoxin, and FDA's guidance recommends testing of components and finished products for pyrogens and endotoxins according to the USP bacterial endotoxins test [3]. Read more.

CJC-1295 is a tetrasubstituted analog of human growth hormone-releasing factor (1-29) with an added maleimide-containing lysine at the C-terminus; in rats it formed a conjugate with serum albumin, and its plasma half-life was extended relative to the unmodified sequence [1]. That albumin-binding group is what the term DAC (drug affinity complex) refers to, and the published human pharmacokinetic data concern this form: in healthy adults, single injections produced dose-dependent increases in GH and IGF-I, with an estimated half-life of 5.8 to 8.1 days [2]. No comparable published human data for a form lacking the albumin-binding group were identified. FDA reports serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and describes the available clinical data as limited [3]. Read more.

GHK is the tripeptide glycyl-histidyl-lysine, and GHK-Cu is its complex with copper(II), described in an author review as activating remodeling-related processes such as collagen synthesis, fibroblast proliferation and increased hair follicle size in cell, animal and some human studies [1]. A 2026 evidence-mapping review concluded that preclinical data consistently point to effects on matrix remodeling, epithelial repair and angiogenesis, but that clinical evidence remains sparse [2]. It noted that a 13-participant post-laser study was negative on objective endpoints, while an 18-participant split-face eyebrow study reported positive cosmetic hair outcomes without defining GHK-Cu speciation or local exposure [2]. Read more.

A 2026 review observed that the literature often treats GHK-Cu as a single active ingredient even though coordination state, speciation, stability and toxicity vary with formulation, and that the studies could not be pooled because formulations, models and endpoints were not commensurable, so topical and injected forms cannot be assumed to be comparable [1]. The cosmetic studies it described were small or incompletely characterized [1]. No controlled human studies of injected GHK-Cu were identified. Read more.

GHRH analogs such as tesamorelin act on the growth hormone-releasing factor receptor of pituitary somatotroph cells to stimulate synthesis and pulsatile release of GH [1]. Ghrelin-receptor agonists, including GHRPs and ipamorelin, act through the separate GHS receptor, and the discovery of ghrelin indicated a GH-regulating pathway distinct from hypothalamic GHRH [2, 3]. WADA's 2026 list names both groups under S2, listing GHRH analogs (for example CJC-1295, sermorelin and tesamorelin) separately from secretagogues and GHRPs (for example ipamorelin, GHRP-2 and GHRP-6) [4]. Read more.

In the original ipamorelin pharmacology paper, all three compounds released GH in swine, but GHRP-2 showed higher potency with lower efficacy than ipamorelin and GHRP-6 [1]. GHRP-6 and GHRP-2 raised plasma ACTH and cortisol in that model, whereas ipamorelin did not [1]. FDA's compounding safety page records different concerns for each, including potential effects on cortisol and blood glucose for GHRP-6, reports of serious adverse events with GHRP-2 (causality not established), and serious adverse events including death in a published intravenous study of ipamorelin [2]. These comparisons come from animal data and regulatory summaries, not head-to-head human trials [1, 2]. Read more.

Tesamorelin is an FDA-approved GHRH analog made from the 44-amino-acid human GRF sequence with a hexenoyl group on the N-terminal tyrosine; it is indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and its elimination half-life after a single subcutaneous dose in healthy subjects was 8 minutes [1]. CJC-1295 is a modified GRF (1-29) analog bearing an albumin-reactive group, and in a trial in healthy adults its estimated half-life was 5.8 to 8.1 days [2, 3]. CJC-1295 is not an approved drug, and FDA lists it among substances for which it has identified serious adverse events and limited clinical data [4]. Read more.

Ipamorelin is a synthetic pentapeptide described in 1998 as a growth hormone secretagogue that releases GH through a GHRP-like receptor, based on work in rat pituitary cells, anaesthetised rats and swine [1]. That receptor class is the GHS receptor, a G-protein-coupled receptor cloned from pituitary and hypothalamus and later shown to bind the stomach peptide ghrelin [2, 3]. In the swine experiments, ipamorelin did not raise ACTH or cortisol beyond the levels seen with GHRH stimulation, unlike GHRP-6 and GHRP-2 [1]. FDA states it lacks sufficient information to know whether most injectable uses of ipamorelin would cause harm in humans, and cites a published study that reported serious adverse events including death with intravenous use for gastric motility [4]. Read more.

In a phase 2 trial of 338 adults with obesity or overweight, the mean percent change in body weight at 48 weeks ranged from -8.7% to -24.2% across retatrutide groups versus -2.1% with placebo, and the most common adverse events were gastrointestinal and dose-related [1]. In the phase 3 TRIUMPH-1 trial (2,339 adults with obesity without diabetes, 80 weeks), the mean change was -17.6% to -25.0% across retatrutide groups versus -3.9% with placebo [2]. In TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes), the mean change ranged from -11.9% to -18.8% versus -5.1% with placebo [3]. The phase 2 trial also reported dose-dependent heart rate increases that peaked at 24 weeks and declined thereafter [1]. Read more.

Under FDA's interim policy for nominated bulk substances, Category 2 holds substances that were nominated with enough information to evaluate but for which FDA has identified significant safety risks; FDA would consider enforcement action against compounders who use them [1]. Category 1 substances are under evaluation and FDA does not intend to act if guidance conditions are met, while Category 3 substances lacked sufficient supporting information [1]. As of FDA's 22 April 2026 update, the active Category 2 table includes peptides such as GHRP-2 and GHRP-6 (503B only; under 503A both are in Category 3 [3]), ibutamoren mesylate (503A and 503B), ipamorelin acetate (503B) and kisspeptin-10 (503A), while BPC-157, TB-500, epitalon and 14 other entries sit in a separate table of nominations withdrawn by their nominators [2]. Moving off the active table did not place those peptides in Category 1; FDA's May 2026 categories document does not list them [3]. Read more.

As of 22 October 2026, Drugs@FDA lists approved applications for semaglutide (Wegovy), tirzepatide (Zepbound) and the oral non-peptide orforglipron (Foundayo, approved 1 April 2026) [1, 2, 3]. Mazdutide was approved in China in June 2025 [4]. No Drugs@FDA application record was returned for retatrutide, survodutide, mazdutide, pemvidutide, VK2735 or cagrilintide; Drugs@FDA lists only approved applications [5]. CagriSema (cagrilintide/semaglutide) was not FDA-approved as of 22 October 2026 [5]. Read more.

The two hormones act through different receptors [1, 2], and combining them has produced larger body-weight changes than either alone in trials. In a phase 2 trial in type 2 diabetes, body-weight change was -15.6% with CagriSema, -5.1% with semaglutide and -8.1% with cagrilintide [3], and in REDEFINE 5 it was -18.4% with CagriSema versus -11.9% with semaglutide alone [4]. Amylin and amylin analogs explained.

Studies of unregulated online products have reported content and purity far from label claims, including semaglutide vials with 7.7% to 14.37% measured purity against a claimed 99% and endotoxin in all tested samples [1]. Visual inspection of those purchases found noncompliance in 59% to 63% of evaluated packaging criteria, and some orders were never delivered [1]. A study of online somatropin vendors found that 70% displayed no medical information, none displayed a regulatory body logo, and all samples contained less somatropin than labeled [2]. An FDA warning letter has also described a seller who labeled products as research use only while its website made claims establishing intended human use [3]. Read more.

CagriSema is a once-weekly fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide [1]. Mean body-weight change at 68 weeks was -20.4% versus -3.0% with placebo in REDEFINE 1 [2] and -13.7% versus -3.4% in adults with type 2 diabetes in REDEFINE 2 [3]. It remained investigational and was not FDA-approved as of 22 October 2026; Drugs@FDA lists approved applications only and returned no record for cagrilintide [4]. Cagrilintide.

Pramlintide (Symlin) was approved in March 2005 for people with type 1 or type 2 diabetes who use mealtime insulin [1, 2]. As of 22 October 2026 its Drugs@FDA products were listed as discontinued, and cagrilintide, eloralintide and amycretin had no Drugs@FDA record; Drugs@FDA lists only approved applications [2, 3]. CagriSema (cagrilintide/semaglutide) was not FDA-approved as of 22 October 2026 [3]. Amylin and amylin analogs explained.

Amylin is a hormone released with insulin from pancreatic beta cells that slows gastric emptying, suppresses glucagon and reduces food intake [1]. Amylin analogs act through the calcitonin receptor paired with RAMP proteins [2], whereas GLP-1 drugs such as semaglutide act on the GLP-1 receptor [3]. Amylin and amylin analogs explained.

Not in the United States. FDA treated Prostamax as an unapproved new drug in a June 2026 warning letter [1]. For epitalon, FDA says it lacks the safety information to know whether it would cause harm [2], and it is not in any 503A category [3], and FDA's briefing document for a July 2026 advisory committee meeting, which reviewed it for insomnia, recommended against adding it to the 503A list [4]. An independent 2026 review found no adequately powered randomized trial establishing efficacy for epitalon [5]. The originating group describes clinical use of related preparations in Russia [6], but we could not confirm current registration status from a regulator's own records, so we make no claim about approval elsewhere. Read more.

Code names are seller labels, not drug names. In 2026 warning letters, FDA identified a product sold as "GLP-3R" as retatrutide [1] and noted that another firm called retatrutide "GLP-1-R peptide" and tirzepatide "GLP-2 peptide" [2]. The second label is confusing because glucagon-like peptide-2 is a separate natural gut hormone with its own receptor [3]. An international nonproprietary name (INN) is a unique, globally recognized name for a pharmaceutical substance [4], so it is the label that links a product to the trial literature; retatrutide (LY3437943) was studied in a phase 2 trial as an agonist of the GIP, GLP-1 and glucagon receptors [5]. We found no authoritative source defining labels such as "R-30", "S-5", "KLOW" or "Wolverine", so their contents can be inferred only from seller descriptions, which this site does not treat as evidence. Read more.

Not by itself. Advisory committee recommendations are non-binding [1], and FDA adds substances to the 503A bulks list through notice-and-comment rulemaking [2]. After the July 2026 votes, FDA's categories document still did not list BPC-157, KPV, TB-500, MOTs-C, semax or epitalon in Category 1 [3]. Compounded drugs, even when lawfully made, are not FDA-approved [4]. Read more.

Cagrilintide is a long-acting amylin analog that activates both amylin and calcitonin receptors [1]. Eloralintide preferentially activates the AMY1 amylin receptor over the calcitonin receptor in cell assays [2]. Amycretin is a single molecule that activates GLP-1, amylin and calcitonin receptors [3]. No head-to-head human trials of these three agents were found. Eloralintide.

The PCAC advises FDA on scientific, technical and medical issues in compounding under sections 503A and 503B and makes recommendations to the Commissioner [1]. Its core of 12 voting members includes representatives of the National Association of Boards of Pharmacy and the US Pharmacopeia, compounding pharmacists, physicians and patient and public health advocates [1]. Its recommendations are non-binding; FDA generally follows them but is not legally bound to do so [2]. In July 2026 it discussed seven peptides nominated for the 503A bulks list [2] and, as reported in The BMJ, recommended six of them [3]; FDA had posted no minutes or vote results as of 22 October 2026 [2]. Read more.

FDA describes a warning letter as its usual notice when it identifies what it believes are significant violations of federal requirements; the letter sets out the concerns, gives the company a chance to address them and asks for a response within a set time [1]. FDA may later issue a close-out letter after evaluating the company's corrective actions [1]. Letters to peptide sellers have asked for a written response within 15 working days and warned that failing to address the matter could lead to legal action such as seizure and injunction [2]. Read more.

Sterility testing under USP <71> looks for living microorganisms [1], while endotoxin testing under USP <85> measures bacterial endotoxin [2]. The two can disagree: freeze-dried semaglutide samples bought online had no viable microorganisms yet all contained endotoxin [3]. Read the guide.

A pharmaceutical-grade compound is one for which a chemical purity standard has been established by a recognized pharmacopeia [1], and in US animal research a non-pharmaceutical-grade substance must be scientifically justified when a pharmaceutical-grade version exists [2]. An unapproved peptide without a compendial monograph does not meet that description regardless of its purity result. Read the guide.

It means the analyte was below the method's detection limit, the lowest amount the method can detect [1]. Without that limit, the result cannot be compared with standards such as USP <232>, whose limits for arsenic, cadmium, lead and mercury differ by route of administration [2]. Read more.

When a seller commissions a test, the laboratory may be independent while the choice of sample and of which reports to publish can stay with the seller. Drug manufacturers may accept a supplier's report only if they run at least one specific identity test themselves and periodically validate the supplier's results [1], and ISO/IEC 17025 sets impartiality requirements for the laboratory, not for the client [2]. Read the guide.

For drugs, cGMP requires laboratory testing of every batch purporting to be sterile [1], and FDA notes the USP <71> test has limited sensitivity because of small sample sizes [2]. No equivalent rule applies to research-labeled material. In a study of online semaglutide vials, the freeze-dried samples had no viable microorganisms yet all contained endotoxin [3]. Read the guide.

It is usually an acceptance criterion, part of a specification, which is a list of tests, procedures and limits a material must meet [1]. A report should also give the measured result and say how purity was defined, because the definition changes the number: in one peptide certified reference material, the trifluoroacetic acid counter-ion was counted as an impurity at nearly 25% by mass, and the final purity assigned by mass was 691 ± 9 mg/g, about 69% [2]. Read more.

Under section 503A, compounders may use bulk drug substances that meet a USP monograph, are components of FDA-approved drugs, or appear on the 503A bulks list, and the list in 21 CFR 216.23 contains six substances, none of them among the peptides discussed on this site [1, 2]. FDA's page on substances that may present significant safety risks (content current April 22, 2026) lists GHRP-2, GHRP-6, ipamorelin acetate, kisspeptin-10 and ibutamoren in category 2, and shows BPC-157, the thymosin beta-4 fragment, CJC-1295, epitalon and thymosin alpha-1 under a separate section of substances nominated but withdrawn [3]. FDA has stated that it does not intend to place substances nominated on or after January 7, 2025 into the interim categories, and that compounded drugs are not FDA-approved [1, 4]. Read more.

Third-party testing means analysis by a laboratory independent of the seller, which corresponds to the validation of supplier results that FDA's regulations expect of manufacturers [1]. Its limits include that a result applies to the sample tested, and in a study of seized products some content could not be quantified because reference standards were lacking at the time [2]. The same study found that of 75 pharmaceuticals analyzed, 33% were substandard and 32% were counterfeit, illustrating how much products can vary [2]. Read more.

Endotoxin was detected in every tested vial in a semaglutide market study, at 2.16 to 8.95 EU/mg, even though the lyophilized samples contained no viable microorganisms at the time of testing [1]. Solid-phase synthesis commonly leaves peptides as trifluoroacetic acid salts, and studies report negative effects of TFA salts in biological assays, which is why counter-ion quantification has been emphasized [2]. For metals, ICH Q3D states that elemental impurities may arise from catalysts, equipment or container closure systems and, because they have no therapeutic role in the product, should be controlled within acceptable limits [3]. FDA also cites immunogenicity risk from aggregation and peptide-related impurities in compounded peptides [4]. Read more.

Amiravo does not provide legal advice. The FDA materials reviewed address distribution: introducing or delivering an unapproved new drug into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, and shipments of laboratory-research drugs under 21 CFR 312.160 require recipient due diligence and record-keeping [1, 2]. Rules on personal possession are not addressed in those documents and may differ by substance and jurisdiction; the legal status page summarizes what is documented. Read more.

The WADA 2026 Prohibited List names BPC-157 among non-approved substances in S0, prohibited at all times [1]. Under S2 it prohibits GHRH analogs (including CJC-1295, sermorelin and tesamorelin), growth hormone secretagogues (including ipamorelin), GHRPs (including GHRP-2 and GHRP-6), growth hormone fragments such as AOD-9604, and growth factors including thymosin-beta4 and its derivatives such as TB-500 [1]. The list says it is updated at least annually, so the current edition should be checked directly [2]. Read more.

Under 21 CFR 312.160, a drug intended solely for tests in vitro or in laboratory research animals may be shipped if labeled "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans," and the shipper must use due diligence that the consignee is conducting such tests [1]. A March 2026 FDA warning letter states that research-use-only labeling did not change the status of products when evidence from the seller's website showed they were intended for human use, which made them unapproved new drugs [2]. The phrase is therefore a labeling statement tied to intended use, and it does not grant permission for human use [1, 2]. Read more.

Mazdutide (IBI362, LY3305677) is a once-weekly synthetic analogue of oxyntomodulin that activates both the GLP-1 and glucagon receptors [1]. Survodutide also targets those two receptors but is a separate molecule from a different developer [2]. Mazdutide was approved in China in June 2025, and in the GLORY-1 phase 3 trial in Chinese adults, mean body-weight change at week 48 was -11.00% and -14.01% versus +0.30% with placebo [3, 4]. Read more.

A prescription product has an FDA-approved label, whereas FDA states that compounded drugs are not FDA-approved, meaning FDA does not verify their safety, effectiveness or quality before they are marketed [1, 2]. Research-grade products sold with research-use-only labels are treated by FDA as unapproved new drugs when the seller's materials show intended human use [3]. Analyses of unregulated online products have found content, purity and endotoxin levels that differed from label claims [4, 5]. Read more.

Animal studies test an intervention in another species, and a review of preclinical models argued that species differences limit how reliably animal findings translate to humans [1]. A study of 101 highly promising basic-science articles found that 27 led to at least one published randomized trial and 5 to licensed clinical use [2]. For compounds such as BPC-157, nearly all published efficacy data are animal data, which is why Amiravo labels the study model beside each finding [3, 4]. Read more.

DAC is commonly expanded as drug affinity complex, a reactive maleimide group added to a peptide so that it conjugates to the Cys34 thiol of serum albumin in vivo and extends plasma half-life, as described for CJC-1295 [1]. Mg and mcg (also written ug) are milligrams and micrograms, a thousandfold difference; the CJC-1295 trial, for example, reports doses in micrograms per kilogram while drug labels such as Egrifta SV use milligrams [2, 3]. IU stands for international unit, which expresses biological activity rather than mass, so its conversion to milligrams is specific to each substance. Read more.

Placebo and nocebo effects influence symptoms after both inert and active treatments, so an uncontrolled personal report cannot separate a product's effect from expectation [1]. For BPC-157, a 2026 systematic review found only three human studies, all judged to be of poor methodological quality, with very low certainty of evidence [2]. Anecdotes are therefore best treated as hypotheses, and controlled trials are the evidence that can test them [1, 2]. Read more.

Peptides are amino acid chains, which FDA's regulations distinguish from proteins at 40 amino acids [1]. SARMs are described as nonsteroidal drugs, while anabolic steroids are steroid-based compounds whose pharmacology involves androgen receptor signaling [2, 3]. WADA classifies anabolic androgenic steroids and SARMs under S1 (anabolic agents) and peptide hormones, growth factors and mimetics under S2, all prohibited at all times [4]. SARMs have been associated with drug-induced liver injury, and none are approved for therapeutic use [2]. Read more.

FDA states that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality before marketing, so one question is whether a product is FDA-approved for the intended condition [1]. Other questions concern the type of evidence behind a compound (human randomized trials, small uncontrolled reports or animal studies only), which for BPC-157 is the last two categories [2]. Athletes may also ask about anti-doping status, since WADA prohibits many of these compounds at all times [3]. Adverse events from approved drugs can be reported to FDA through MedWatch [4]. Amiravo provides information only and does not give medical advice. Read more.

Semaglutide, tirzepatide, tesamorelin and bremelanotide have completed the trials needed for FDA-approved labels [1, 2, 3, 4]. Retatrutide has published phase 2 and phase 3 trial reports but is not approved [5, 6, 7]. CJC-1295 was tested in randomized placebo-controlled trials in healthy adults, and thymosin beta-4 has had a phase 2 eye-drop trial and a phase 1 intravenous study, but neither trial tested the TB-500 fragment [8, 9, 10]. For BPC-157, a 2026 review found only three small, poor-quality human studies, and a phase 1 trial registered in 2015 has an unknown status [11, 12]. Read more.

Content and purity are separate measurements, and a content figure depends on how it was calculated, including whether counterions are counted; in one certified reference material TFA made up nearly 25% of the mass [1]. Testing of online semaglutide vials found content 28.56% to 38.69% above the label alongside purity of 7.7% to 14.37% [2], so a high content figure is not on its own a sign of quality. Read the guide.

ISO/IEC 17025 specifies requirements for a laboratory's competence, impartiality and consistent operation [1]. Accreditation is granted for specific methods, listed on the laboratory's scope of accreditation [2], so it does not cover methods outside that scope, and it does not by itself show that a sample came from the lot being sold. Read the guide.

No. Orforglipron is a synthetic nonpeptide agonist of the GLP-1 receptor [1]. It was approved by the FDA as Foundayo, a once-daily oral tablet for long-term weight management, on 1 April 2026 [2, 3]. Oral semaglutide, by contrast, is a peptide tablet [4]. Read more.

VK2735 is an investigational GLP-1 and GIP receptor dual agonist peptide [1]. In the 13-week VENTURE phase 2 trial, mean body-weight change ranged from -9.1% to -14.7% across four weekly doses versus -1.7% with placebo [1]. A 78-week phase 3 trial is registered as active, and an oral formulation is in separate trials [2, 3]. Read more.

Pemvidutide (ALT-801) is an investigational GLP-1 and glucagon receptor dual agonist with closely matched potency at both receptors [1]. In the 24-week IMPACT phase 2b analysis in biopsy-confirmed MASH, MASH resolution without fibrosis worsening occurred in 58% and 52% of the pemvidutide groups versus 20% with placebo, but fibrosis improvement did not differ significantly from placebo [2]. The trials were sponsored by the developer [2]. Read more.

No. Nothing on this site is medical advice or a recommendation to use any compound in people or animals. The compounds described are research materials for laboratory use only.

Dosing information is outside the scope of a research-use-only reference. Our calculators perform laboratory arithmetic, such as concentration and dilution, and do not provide dosing guidance.

Every compound carries one of four labels, from “Evidence not yet assessed” to “Limited human data.” The full definitions are in our guide on how we label evidence. Read the guide.

Summaries are written in-house in plain language. Chemical identifiers are checked against PubChem, and each page lists peer-reviewed references from PubMed where suitable sources exist. Pages without verified references say so.

Batch test reports will appear on the relevant compound page only when real documents from an independent laboratory exist. We do not display purity claims without them.

Some compounds are under review before they are listed, including approved drug compounds and investigational drugs. They will appear only if review allows it.

Use the contact form and choose “Correction.” Please include the page and the source you are relying on, and we will review it.